Osteoporosis International

, Volume 21, Issue 5, pp 837–846 | Cite as

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

  • D. L. Kendler
  • L. Bessette
  • C. D. Hill
  • D. T. Gold
  • R. Horne
  • S. F. Varon
  • J. Borenstein
  • H. Wang
  • H.-S. Man
  • R. B. Wagman
  • S. Siddhanti
  • D. Macarios
  • H. G. Bone
Original Article

Abstract

Summary

The Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly oral tablet for treatment of bone loss. Patients preferred and were more satisfied with a treatment that was administered less frequently, suggesting the acceptability of the 6-month injection for treatment of bone loss.

Introduction

The PSQ compares patient preference and satisfaction between a 6-month subcutaneous injection and a weekly oral tablet for treatment of bone loss.

Methods

Postmenopausal women with low bone mass who enrolled in two separate randomized phase 3 double-blind, double-dummy studies received a 6-month subcutaneous denosumab injection (60 mg) plus a weekly oral placebo or a weekly alendronate tablet (70 mg) plus a 6-month subcutaneous placebo injection. After 12 months, patients completed the PSQ to rate their preference, satisfaction, and degree of bother with each regimen.

Results

Most enrolled patients (1,583 out of 1,693; 93.5%) answered ≥1 item of the PSQ. Significantly more patients preferred and were more satisfied with the 6-month injection versus the weekly tablet (P < 0.001). More patients reported no bother with the 6-month injection (90%) than the weekly tablet (62%).

Conclusion

Patients preferred, were more satisfied, and less bothered with a 6-month injection regimen for osteoporosis.

Keywords

Injection Osteoporosis Preference Questionnaire Satisfaction Tablet 

Supplementary material

198_2009_1023_MOESM1_ESM.doc (44 kb)
Supplementary Table 1PSQ responses by language and country for the questions: “Which do you prefer?” and “With which frequency of administration have you been more satisfied?” (DOC 44 kb)

References

  1. 1.
    Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497CrossRefPubMedGoogle Scholar
  2. 2.
    Wahl C, Gregoire JP, Teo K et al (2005) Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes. Healthc Qual 8:65–70Google Scholar
  3. 3.
    Kothawala P, Badamgarav E, Ryu S et al (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501CrossRefPubMedGoogle Scholar
  4. 4.
    Reginster JY, Rabenda V, Neuprez A (2006) Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38:S2–S6CrossRefPubMedGoogle Scholar
  5. 5.
    Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022CrossRefPubMedGoogle Scholar
  6. 6.
    Gold DT, Martin BC, Frytak JR et al (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585–594CrossRefPubMedGoogle Scholar
  7. 7.
    van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE et al (2006) Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 22:1757–1764CrossRefPubMedGoogle Scholar
  8. 8.
    Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008CrossRefPubMedGoogle Scholar
  9. 9.
    Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928CrossRefPubMedGoogle Scholar
  10. 10.
    McCombs JS, Thiebaud P, McLaughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287CrossRefPubMedGoogle Scholar
  11. 11.
    Papaioannou A, Ioannidis G, Adachi JD et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808–813CrossRefPubMedGoogle Scholar
  12. 12.
    Stafford RS, Drieling RL, Hersh AL (2004) National trends in osteoporosis visits and osteoporosis treatment, 1988–2003. Arch Intern Med 164:1525–1530CrossRefPubMedGoogle Scholar
  13. 13.
    Watson J, Wise L, Green J (2007) Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 63:843–849CrossRefPubMedGoogle Scholar
  14. 14.
    Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124CrossRefPubMedGoogle Scholar
  15. 15.
    Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082CrossRefPubMedGoogle Scholar
  16. 16.
    Kendler D, Kung AW, Fuleihan Gel H et al (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243–251CrossRefPubMedGoogle Scholar
  17. 17.
    Simon JA, Lewiecki EM, Smith ME et al (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871–1886CrossRefPubMedGoogle Scholar
  18. 18.
    Burgess TL, Qian Y, Kaufman S et al (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527–538CrossRefPubMedGoogle Scholar
  19. 19.
    Kostenuik P, Nguyen H, McCabe J et al (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182–195CrossRefPubMedGoogle Scholar
  20. 20.
    Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176CrossRefPubMedGoogle Scholar
  21. 21.
    Bone HG, Bolognese MA, Yuen CK et al (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149–2157CrossRefPubMedGoogle Scholar
  22. 22.
    Cummings SR, McClung MR, Christiansen C et al (2008) The effects of denosumab on fracture risk in women with osteoporosis. Osteoporos Int 20:167Google Scholar
  23. 23.
    Lewiecki EM, Miller PD, McClung MR et al (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 22:1832–1841CrossRefPubMedGoogle Scholar
  24. 24.
    McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831CrossRefPubMedGoogle Scholar
  25. 25.
    Miller PD, Bolognese MA, Lewiecki EM et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222–229CrossRefPubMedGoogle Scholar
  26. 26.
    Emkey R, Koltun W, Beusterien K et al (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895–1903CrossRefPubMedGoogle Scholar
  27. 27.
    Hadji P, Minne H, Pfeifer M et al (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 75:303–310CrossRefPubMedGoogle Scholar
  28. 28.
    McClung M, Recker R, Miller P et al (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122–128CrossRefPubMedGoogle Scholar
  29. 29.
    Gold DT, Horne R, Hill C et al (2008) Development, reliability, and validity of a new preference satisfaction questionnaire. J Bone Miner Res 23:S210–S211Google Scholar
  30. 30.
    Kendler DL, Benhamou CL, Brown JP et al (2008) Effects of denosumab in postmenopausal women transitioning from alendronate therapy in comparison with continued alendronate. Osteoporos Int 9(Suppl 2):S385–S386Google Scholar
  31. 31.
    Brown JP, Prince RL, Deal C et al (2008) Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res . doi:10.1359/jbmr.080910 PubMedGoogle Scholar
  32. 32.
    Cramer JA, Gold DT, Silverman SL et al (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–1031CrossRefPubMedGoogle Scholar
  33. 33.
    Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38:S4–S9CrossRefPubMedGoogle Scholar
  34. 34.
    Solomon DH, Avorn J, Katz JN et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419CrossRefPubMedGoogle Scholar
  35. 35.
    Saltman DC, Sayer GP, O'Dea NA (2006) Dosing frequencies in general practice—whose decision and why? Aust Fam Physician 35:915–919PubMedGoogle Scholar
  36. 36.
    Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310CrossRefPubMedGoogle Scholar
  37. 37.
    Brankin E, Walker M, Lynch N et al (2006) The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 22:1249–1256CrossRefPubMedGoogle Scholar
  38. 38.
    Cramer JA, Amonkar MM, Hebborn A et al (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460CrossRefPubMedGoogle Scholar
  39. 39.
    Cramer JA, Lynch NO, Gaudin AF et al (2006) The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28:1686–1694CrossRefPubMedGoogle Scholar
  40. 40.
    Ettinger MP, Gallagher R, MacCosbe PE (2006) Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 12:522–528PubMedGoogle Scholar
  41. 41.
    Payer J, Killinger Z, Sulkova I et al (2008) Preferences of patients receiving bisphosphonates—how to influence the therapeutic adherence. Biomed Pharmacother 62:122–124CrossRefPubMedGoogle Scholar
  42. 42.
    Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905CrossRefPubMedGoogle Scholar
  43. 43.
    Saag K, Lindsay R, Kriegman A et al (2007) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40:1238–1243CrossRefPubMedGoogle Scholar
  44. 44.
    Horne R, Kovacs C, Katlama C et al (2009) Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives? AIDS Res Ther 6:2CrossRefPubMedGoogle Scholar
  45. 45.
    Gruffydd-Jones K, Hood CA, Price DB (1997) A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia 17:31–36CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  • D. L. Kendler
    • 1
  • L. Bessette
    • 2
  • C. D. Hill
    • 3
  • D. T. Gold
    • 4
  • R. Horne
    • 5
  • S. F. Varon
    • 6
    • 7
  • J. Borenstein
    • 7
  • H. Wang
    • 7
  • H.-S. Man
    • 8
  • R. B. Wagman
    • 9
    • 10
  • S. Siddhanti
    • 7
  • D. Macarios
    • 7
  • H. G. Bone
    • 11
  1. 1.Prohealth Clinical ResearchUniversity of British ColumbiaVancouverCanada
  2. 2.Le Centre Hospitalier Universitaire de QuébecPavillon CHULQuebec CityCanada
  3. 3.RTI Health SolutionsRTI InternationalResearch Triangle ParkUSA
  4. 4.Center for AgingDuke University Medical CenterDurhamUSA
  5. 5.Centre for Behavioral Medicine, The School of PharmacyUniversity of LondonLondonUK
  6. 6.AllerganIrvineUSA
  7. 7.Amgen Inc.Thousand OaksUSA
  8. 8.Amgen Inc.CambridgeUK
  9. 9.Amgen Inc.South San FranciscoUSA
  10. 10.Stanford University School of MedicineStanfordUSA
  11. 11.Michigan Bone and Mineral Clinic, P.C.DetroitUSA

Personalised recommendations